 |
Journal articles
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
Pieternella Lugtenburg
Irit Avivi
1
Henriette Berenschot
Osman Ilhan
Jean Pierre Marolleau
2
Arnon Nagler
3
Antonio Rueda
Monica Tani
Mehmet Turgut
Stuart Osborne
Rodney Smith
Michael Pfreundschuh
4
Adrian Tempescul
5
Adrian Tempescul 5
Author
1
Tel Aviv Sourasky Medical Center [Te Aviv] (64239, Tel Aviv - Israel)
2
CHU - Centre Hospitalier Universitaire d'Amiens (Service de Néphrologie Médecine Interne Centre Hospitalier d'Amiens 80054 Amiens Cedex, France - France)
3
Service d'Hématologie [AP-HP Hôpital Saint-Antoine] (184 Rue du Faubourg Saint-Antoine, 75012 Paris - France)
- CHU Saint-Antoine [AP-HP] (184, rue du Faubourg Saint-Antoine 75571 Paris cedex 12 - France)
4
Saarland University Medical School (José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Homburg/Saar - Germany)
- Saarland University Medical School (France)
5
CIC Brest (Boulevard Tanguy Prigent 29609 Brest Cedex - France)
- UBO - Université de Brest (Université de Bretagne Occidentale - 3 Rue des Archives 29238, Brest - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : CIC1412 (101, rue de Tolbiac, 75013 Paris - France)
- Hôpital de la Cavale Blanche (Boulevard Tanguy Prigent 29609 Brest Cedex - France)
Document type :
Journal articles
Complete list of metadatas
https://hal.univ-brest.fr/hal-02049783
Contributor : Ghislaine Calvez <>
Submitted on : Tuesday, February 26, 2019 - 4:10:29 PM
Last modification on : Wednesday, August 19, 2020 - 11:58:42 AM
Contributor : Ghislaine Calvez <>
Submitted on : Tuesday, February 26, 2019 - 4:10:29 PM
Last modification on : Wednesday, August 19, 2020 - 11:58:42 AM
Identifiers
- HAL Id : hal-02049783, version 1
Collections
Citation
Pieternella Lugtenburg, Irit Avivi, Henriette Berenschot, Osman Ilhan, Jean Pierre Marolleau, et al.. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica, Ferrata Storti Foundation, 2017, 102 (11), pp.1913-1922. ⟨hal-02049783⟩
Metrics
Record views